ALEC Alector1.57-1.64 (-51.1%)
Premarket Decliner
ALEC Alector3.21-0.10-3.0%
Premarket:1.57-1.64 (-51.3%)
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
Globe NewswireTue, 21-Oct 4:05 PM
ALEC Alector2.97+0.21 (+7.6%)
ALEC Alector2.22+0.07 (+3.3%)
ALEC Alector1.90+0.44 (+30.1%)